Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Current evidence and ongoing trials exploring left atrial appendage closure in AF-related stroke

Ana Catarina Fonseca, MD, PhD, MPH, University of Lisbon, Lisbon, Portugal, discusses the current evidence for left atrial appendage closure in patients with atrial fibrillation (AF) who have had an ischemic stroke, highlighting that most trials have been non-inferiority trials, which have limitations in establishing equivalence to anticoagulation. Dr Fonseca notes that there is a lack of data regarding patients with a high risk of bleeding, such as those with intracerebral hemorrhage or microbleeds, and that ongoing trials aim to address these gaps. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Well, it’s a provocative title actually. So what I’m going to talk mainly about is about all the evidence that we have until now. And unfortunately, most trials until now have been non-inferiority trials. We know that it works, but actually having a non-inferiority trial is actually not the same as saying that treatment is equal to another one. It just says that we are able to say that we are willing to give up some benefit in order to have or do that treatment instead...

Well, it’s a provocative title actually. So what I’m going to talk mainly about is about all the evidence that we have until now. And unfortunately, most trials until now have been non-inferiority trials. We know that it works, but actually having a non-inferiority trial is actually not the same as saying that treatment is equal to another one. It just says that we are able to say that we are willing to give up some benefit in order to have or do that treatment instead. We have some evidence that left atrial occlusion is non-inferior to anticoagulation in patients who had atrial fibrillation. Mainly in patients, some of them that have a high risk or high CHADS scores, but we still have a lack of data regarding patients with a high risk of bleeding. And mainly patients with intracranial hemorrhage or patients that have microbleeds. There are several ongoing trials. That’s where data is actually lacking. There is a registry, but that’s it. So we know that it may be useful, but still we have to improve the procedure itself so that it can be used in a more generalized way. So we still have a long way to go because most of the trials that have been done now are non-inferiority trials. So we need more data and there’s a lot of things coming up in the future actually.

Yeah, so there are going to be several trials that are going to evaluate different aspects of left atrial appendage closure. One of them is to test this procedure in patients that actually have had intracranial hemorrhage or have had microbleeds. So that’s one of the main areas where clinical trials are going to be looking for. Another major area is taking into account the data from LAAOS-3. LAAOS-3 was a trial in which they used surgical left appendage closure instead of percutaneous. So it was an opportunistic intervention actually. There were patients with atrial fibrillation and they were undergoing surgery for other motives and they decided also to do the left atrial appendage closure. So what they saw actually was that after appendage closure plus anticoagulation versus only anticoagulation itself was better to reduce the number of ischemic events or subsequent events and systemic embolism. So taking that into account, some trials that are going to be conducted like LAAOS-4 and ELAPSE, are going to see if percutaneous left atrial appendage occlusion plus anticoagulation is actually better than just anticoagulation to reduce the number of patients that have systemic embolism or that also have stroke. And there’s another set of clinical trials that are going to evaluate a very specific area that’s about what’s the best antithrombotic treatment to do after appendage closure because we know that when the device is placed there’s immediately a very high risk of thrombosis in situ because the device has got to undergo a process of endothelialization so that it’s not exposed. And so several trials are going to evaluate what’s the best strategy. There’s a low dose of novel anticoagulant, just aspirin, double antiplatelet therapy. So as you can see, there are different types of clinical trials that are going to be done to try to evaluate different strategies of antithrombotics plus LAC and also different populations.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.